

**Table 2. Efficacy Outcomes During and After the Treatment Period, According to Prior Treatment Response and According to Baseline Predictor Variables**

Efficacy Outcome, n/N (%)	Previous Response					Total
	Null response	Null response	Partial response	Viral breakthrough	Relapse	
	T12PR24 n = 24	T12PR48 n = 27	n = 29	n = 8	n = 29	N = 117
	<i>Number/total number (percent)</i>					
HCV RNA undetectable during treatment period						
Week 2	0/24 (0)	2/27 (7)	8/29 (28)	4/4 (50)	14/29 (48)	28/117 (24)
Week 4	5/24 (21)	16/27 (59)	25/29 (86)	7/8 (88)	27/29 (93)	80/117 (68)
Week 12	7/24 (29)	23/27 (85)	24/29 (83)	6/8 (75)	26/29 (90)	86/117 (74)
End of treatment	6/24 (25)	19/27 (70)	23/29 (79)	6/8 (75)	29/29 (100)	83/117 (71)
Sustained virologic response						
All patients	4/24 (17)	15/27 (56)	16/29 (55)	6/8 (75)	28/29 (97)	69/117 (59)
By race						
White	4/22 (18)	13/24 (54)	15/27 (56)	5/7 (71)	25/26 (96)	62/106 (58)
Black	0/2 (0)	2/3 (67)	0/1 (0)	1/1 (100)	2/2 (100)	5/9 (56)
By ethnicity						
Hispanic/Latino	0/2 (0)	1/2 (50)	2/3 (67)	NA	2/2 (100)	5/9 (56)
Not Hispanic/Latino	4/22 (18)	14/25 (56)	14/26 (54)	6/8 (75)	26/27 (100)	64/108 (59)
By HCV genotype 1 subtype						
1a	2/14 (14)	9/16 (56)	8/17 (41)	5/5 (100)	17/17 (100)	41/69 (59)
1b	1/8 (12)	6/10 (60)	5/7 (71)	1/3 (33)	9/10 (90)	22/38 (58)
By HCV RNA levels						
HCV RNA ≥800,000 IU/mL	4/23 (17)	15/27 (56)	13/25 (52)	1/3 (33)	18/19 (95)	51/97 (53)
HCV RNA <800,000 IU/mL	0/1 (0)	NA	3/4 (75)	5/5 (100)	10/10 (100)	18/20 (90)
By stage of fibrosis (%)						
None or minimal fibrosis	1/5 (20)	0/6 (0)	7/8 (88)	2/2 (100)	8/8 (100)	18/29 (62)
Portal fibrosis	3/8 (38)	8/10 (80)	4/9 (44)	1/2 (50)	14/15 (93)	30/44 (68)
Bridging fibrosis	0/9 (0)	6/9 (67)	3/7 (43)	3/4 (75)	5/5 (100)	17/34 (50)
Cirrhosis	0/2 (0)	1/2 (50)	2/5 (40)	NA	1/1 (100)	4/10 (40)
Relapse						
All patients	2/6 (33)	4/19 (21)	6/23 (26)	0/6 (0)	1/29 (3)	13/83 (16)
Patients who completed treatment	1/5 (20)	3/16 (19)	5/21 (24)	0/6 (0)	0/26 (0)	9/74 (12)
Patients who stopped treatment prematurely	1/1 (100)	1/3 (33)	1/2 (50)	NA	1/3 (33)	4/9 (44)